BMJ Open

Associations between use of psychotropic medications and use of hormonal contraception among girls and women aged 15–49 years in Finland: a nationwide, register-based, matched case–control study

Elena Toffol, Timo Partonen, Oskari Heikinheimo, Anna But, Antti Latvala, Jari Haukka

ABSTRACT

Objectives The relationship between the use of contraception and of psychiatric medications is understudied. We examined whether the current and past use of psychotropic medications is associated with the use and type of hormonal contraception (HC).

Design Nationwide register-based matched case–control study.

Settings All fertile-aged (15–49 years) girls and women living in Finland in 2017; data from several national registers.

Participants 294 356 girls and women with a redeemed prescription of HC in 2017, and their same-sized control group of non-users (n=294 356) identified through the Prescription Centre.

Main outcome measures Associations between the use of psychotropic medications and the use of HC, and the type of HC tested in logistic regression models.

Results Altogether 19.5% of the HC users, and 18% of the HC non-users received at least one prescription for a psychotropic medication in 2017. Among HC users, the proportions of occasional and regular users of psychotropic medications in 2013–2016 were 4.5% and 14.8%, while among HC non-users the respective figures were 4.3% and 14.6%, respectively. In multivariable logistic regression models both the use of psychotropic medications in 2017, and their occasional or regular use between 2013–2016 were associated with higher odds of HC use, although with small to very small effect sizes (ORs between 1.37 and 1.06 and 95% CIs 1.22 to 1.53, and 1.03 to 1.09, respectively). After adjustment for covariates, when fixed combinations of progestogens and oestrogens for systemic use was the reference category, women using almost any class of psychotropic medications had higher odds of using other types of HC.

Conclusions Fertile-aged girls and women with current and past use of psychotropic medications have higher odds of using HC, with a specific pattern in the type of contraceptives used. Further research is warranted to examine whether our observations indicate a reduction of unwanted pregnancies in women with psychiatric disorders.

INTRODUCTION

The relationship between the use of hormonal contraception (HC) and women’s mental health continues to be debated. While ample evidence has been provided showing no associations between the use of contraception and the increased risk of depressive or anxiety disorders, findings from recent studies are challenging this view. Recent observations report that women using HC (especially oral contraceptives, OC) have higher odds of depression, and of suicidal behaviour, with a long-term risk of depression later in adulthood for those who started their OC use during adolescence.

However, while these findings indicate a link between contraceptive use and mental health status, the reverse association is likewise plausible and of public health and clinical
relevance. Women suffering from psychiatric disorders seem to have higher risk of unplanned pregnancy and induced abortion, as well as risky sexual behaviour including non-use or inconsistent use of contraception, or use of less effective contraceptive methods. 

For instance, among teenagers and young women, those with baseline depressive and stress symptoms had higher odds of reporting mood changes, of OC discontinuation and of inconsistent use of contraception. It has been hypothesised that a subgroup of women may be more sensitive to hormonal fluctuations, and thus more prone to develop mood symptoms or disorders in relation to reproductive events (e.g., the premenstrual phase, the postpartum or the perimenopause), as well as while on contraception. Consequently, women with mental health problems, either because they are more likely to experience mood side effects of HC or to consider their perceived mood changes as caused by HC, are also more likely to discontinue contraception use. In line with these observations, we previously found that a recent care episode for a psychiatric disorder was associated with lower odds of HC use among almost 600 000 women aged 15–49 years in Finland. The study used register records with a psychiatric discharge diagnosis in 2016, thus including only the most severe cases of psychiatric disorders. However, because mild and moderate mental disorders not requiring hospitalisation are highly prevalent in the population, the overall relationship between mental health and HC use remains largely unknown. Thus, the aim of this study was to explore the associations between the current and previous prescriptions of psychotropic medications, and HC use in 2017, in a population inclusive of all fertile-aged women using HC in Finland, and their reference group of non-users. A further aim was to test whether the use of psychotropic medications was associated with the type of HC used.

**METHODS**

This work is part of a larger register-based study on HC in Finland, described in detail elsewhere. Briefly, the population was selected on the basis of the unique personal identification number given at birth or at immigration to each person permanently residing in Finland. The group of HC users, selected from the Prescription Centre in the Kanta Services, included all fertile-aged girls and women (15–49 years) with at least one redeemed prescription for HC in 2017 (n=294 445). The same-sized control group of HC non-users included women, matched by age and municipality of residence, with no redeemed HC prescriptions in 2017. Altogether 89 women who received a prescription with Anatomical Therapeutic Chemical (ATC) code ‘G03AD’ (i.e., emergency contraception, which is usually available without prescription in Finland), and their matched controls, were excluded, leaving a final population of 588 712 women. As such, the study population included 52% of all fertile-aged girls and women living in Finland in 2017.

**The registers**

Information on redeemed medications for each person living in Finland is stored in the Prescription Centre, a centralised database in the Kanta Services. The recorded data include, among others, the product ATC code, date of prescription and of purchase and the redeemed amount in defined daily dose (DDD). In addition to selection of the study population, the Prescription Centre was used to gather information on redeemed prescriptions for psychotropic medications between 2013 and 2017 for all the study members. Use of psychotropic medications in 2017 was defined as one or more redeemed prescriptions in the same year. Users of psychotropic medications between 2013 and 2016 were divided into occasional and regular users, defined as women with only one versus two or more redeemed prescriptions of the same class drug.

The examined HC types included intrauterine device (IUD) with progestogen (i.e., the levonorgestrel-releasing intrauterine system, LNG-IUS, ATC code G02BA); vaginal ring with progestogen and oestrogen (G02BB); progestogens and oestrogens, fixed combinations—including monophasic combined OCs and transdermal patch (G03AA); progestogens and oestrogens, sequential preparations for systemic use (G03AB); progestogens for systemic use (G03AC); and cyproterone and oestrogen (G03HB01). Psychotropic medications included anti-psychotics (N05A), anxiolytics (N05B), hypnotics/sedatives (N05C), antidepressants (N06A), psychostimulants (N06B), psycholeptics and psychoanaleptics in combination (N06C).

The Population Register Centre contains basic information of all Finnish citizens and foreign citizens residing permanently in Finland. From this register we obtained information on age, municipality of residence, civil status, socioeconomic group, highest level of education, and annual income of all the study members on 31 December 2017.

The Medical Birth Register includes data on all live births and stillbirths in Finland since 1987; the Register of Induced Abortions contains data on induced abortions since 1983, and the Register of Sterilisations on all sterilisations since 1987. Based on these registers, we gathered information on pregnancies with birth dates in 2016 and 2017, induced abortions performed in 2016 and 2017 and sterilisations between 1987 and 2016.

The Care Register for Healthcare, which includes data on inpatient care in hospitals, health centres, day surgeries and specialised outpatient care, was used to identify women who had received a psychiatric diagnosis (International Classification of Diseases, 10th Revision codes F01–F19—substance abuse, F30–F39—mood disorders, F40–F48—anxiety disorders, F50—eating disorders and F60—personality disorders) between 2013 and 2016.

**Statistical analyses**

The frequency of use of each class of psychotropic medications among HC users and non-users was compared via $\chi^2$ test. We assessed the percentages of women using
each type of HC within users of categories of psychotropic medications. Women with redeemed prescriptions of two or more different types of HC in 2017 were classified on the basis of their first redeemed prescription.

Associations between use of each class of psychotropic medications and HC use were tested via univariable (BL-Model 1) and multivariable binary logistic regression models using the ‘gnm’ R-package,19 which, through the argument ‘eliminate’, allows for handling parameters of stratification factors with a large number of levels (in our case, ‘municipality of residence’). Separate models were conducted to test the associations with the use of psychotropic medications in 2017, and with occasional or regular use from 2013 to 2016. Multivariable models were progressively adjusted for age group, marital status and education level (BL-Model 2) and reproductive characteristics (pregnancies in 2017, induced abortions in 2016–2017 and sterilisation before 2017) (BL-Model 4). A separate fully adjusted model further tested the interaction between age and use of psychotropic medications; if there was a significant interaction, age-stratified multivariable analyses were performed.

To further confirm the results and take into account a potential ‘healthcare user bias’, sensitivity analyses were conducted using the purchased amount in DDD as indicator of use of psychiatric medications between 2013 and 2016. To this end, the total purchased DDD for each class was divided into tertiles, and groups of low, intermediate and high-level users were created accordingly. Because of the data distribution with duplicate values, only two groups were created for high and low level users of hypnotics/sedatives (cut-off at the 50th percentile), and of psycholeptics and psychoanalectics in combination (cut-off at the 60th percentile).

We further examined whether the odds of using distinct types of HC in 2017 differed by occasional or regular use of psychotropic medications between 2013 and 2016. To this end, we conducted univariable (ML-Model 1) and multivariable multinomial logistic regression models among HC users, controlling for age, marital and socioeconomic status, education and income levels (ML-Model 2) and reproductive characteristics (pregnancies or induced abortions in 2016–2017) (ML-Model 3). Because of the relatively small number of women using psychostimulants or psycholeptics and psychoanalectics in combination, these classes were excluded from these analyses. Sensitivity analyses were additionally performed using groups of users based on the purchased DDD, as described above.

For all the analyses, the two-tailed p values of <0.05 were considered statistically significant. All the analyses were performed with R software V.3.5.1.20

Patient and public involvement
Patients and the public were not directly involved in the research process.

RESULTS
A quarter (25.6%, n=294 356) of all fertile-aged girls and women in Finland were using HC in 2017. Their characteristics as well as those of the control women (n=294 356) are described in detail elsewhere.17 The proportions of different used HC types are illustrated in online supplemental figure 1.

Use of psychotropic medications in 2017
Altogether 110 112 (18.7%) women had redeemed at least one prescription of a psychotropic medication in 2017; of them, 52% (n=57 478) used also HC. The proportions of women using and not using HC who also had one or more prescriptions of psychotropic medications by ATC codes are reported in table 1.

In univariable logistic regression models the use of psychotropic medications in 2017 was associated with higher odds of HC use (ORs: any medication=1.12; anxiolytics=1.10; hypnotics/sedatives=1.17; antidepressants=1.11; psycholeptics and psychoanalectics in combination=1.30, p<0.0001). The associations remained after controlling for age group, education and income levels, marital and socioeconomic status and reproductive characteristics. Additionally, in partially and fully adjusted models, the use of antipsychotics was also associated with higher odds of being a HC user (ORs=1.10 to 1.09, p<0.0001) (table 2).

Table 1 Proportions of HC users and non-users receiving one or more prescriptions for psychotropic medications in 2017

| Class of psychotropic medication ATC code, class | HC users | HC non-users | P value |
|-----------------------------------------------|---------|-------------|---------|
| Any psychotropic medication                   | 57 478  (19.5%) | 52 634 (17.9%) | <0.0001 |
| N05A, antipsychotics                          | 11 136 (3.8%) | 11 688 (4.0%) | 0.0002 |
| N05B, anxiolytics                             | 17 181 (5.8%) | 15 744 (5.4%) | <0.0001 |
| N05C, hypnotics/sedatives                     | 17 829 (6.1%) | 15 397 (5.2%) | <0.0001 |
| N06A, antidepressants                         | 40 488 (13.8%) | 37 028 (12.6%) | <0.0001 |
| N06B, psychostimulants                        | 1681 (0.57%) | 1715 (0.58%) | 0.570 |
| N06C, psycholeptics and psychoanalectics (amitriptyline) in combination | 1237 (0.4%) | 952 (0.3%) | <0.0001 |

ATC, Anatomical Therapeutic Chemical; HC, hormonal contraception.
There was a significant interaction between age and a recent prescription of psychotropic medications, except for psycholeptics and psychostimulants in combination. Regardless of the type of medication, the proportions of HC users among those with a recent psychotropic prescription were consistently higher especially in teenagers but lower in the young age group (20–24 years) as compared with non-users. Among those with a recent psychiatric prescription, the highest rates of using HC were seen for teenagers (varying from 54.6% for antipsychotics to 55.8% for antidepressants, and 57.5% for anxiolytics and sedatives/hypnotics) (online supplemental figures 2 and 3).

Use of psychotropic medications between 2013 and 2016

A total of 112,609 women of our study population redeemed at least one prescription of a psychotropic medication between 2013 and 2016; of them, 20.8% (n=23,379) received a psychiatric diagnosis in the same period according to the records in the Care Register for Healthcare; conversely, 18.5% (n=5302) of the 28,681 women with a psychiatric diagnosis between 2013 and 2016 had not redeemed any psychiatric prescriptions. Approximately 15% of the women (n=86,644) were regular users of psychotropic medications in the period 2013–2016, while 4.4% (n=25,965) received only one psychiatric prescription (table 3, left side).

Higher odds for using HC were predicted by (occasional and regular) use of hypnotics/sedatives and psycholeptics and psychostimulants, and by regular use of antipsychotics during 2013–2016 in unadjusted logistic regression models. On the contrary, occasional and regular use of antipsychotics and regular use of anxiolytics were associated with lower odds of HC use (table 4). After adjustment for sociodemographic and health-related covariates, the use of almost all the classes of psychiatric medications predicted belonging to the HC user group, although with small to very small effect sizes (ORs ranging between 1.06 and 1.37).

Sensitivity analyses using quantities of redeemed DDD as indicator of psychotropic drug use (table 3, right side) substantially confirmed these findings. Specifically, women with higher use (ie, belonging to the highest levels of redeemed DDD) of all psychotropic medications had higher odds of using HC compared with women with lower use (ie, belonging to the lowest levels of redeemed DDD). However, in the case of antipsychotics and regular use of anxiolytics, this association was not statistically significant.

There was a significant age×psychotropic medication interaction in predicting HC use for all the medication classes considered, with the exception of psycholeptics and psychostimulants. In detail, among occasional and regular users of psychotropic medications, the odds of HC use tended to be lower (than in non-users of psychotropic medications) in teenagers and young women as compared with those in the young age group (20–24 years) and in older women (≥25 years).

Table 2: Associations between prescriptions of psychotropic medications in 2017 and HC use in 2017

| Psychotropic medication, ATC code, class | Model 1 OR 95% CI P value | Model 2 OR 95% CI P value | Model 3 OR 95% CI P value | Model 4 OR 95% CI P value |
|----------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| Any psychotropic medication            | 1.12 (1.10 to 1.13) <0.0001 | 1.15 (1.13 to 1.16) <0.0001 | 1.16 (1.14 to 1.17) <0.0001 | 1.15 (1.13 to 1.17) <0.0001 |
| N05A, antipsychotics                   | 0.95 (0.93 to 0.98) 0.00019 | 1.02 (0.99 to 1.05) 0.212 | 1.10 (1.07 to 1.13) 0.0001 | 1.09 (1.06 to 1.12) 0.0001 |
| N05B, anxiolytics                      | 1.10 (1.07 to 1.12) 0.0001 | 1.14 (1.12 to 1.17) 0.0001 | 1.16 (1.14 to 1.19) 0.0001 | 1.16 (1.14 to 1.19) 0.0001 |
| N05C, hypnotics/sedatives              | 1.17 (1.14 to 1.20) 0.0001 | 1.19 (1.16 to 1.21) 0.0001 | 1.18 (1.15 to 1.20) 0.0001 | 1.17 (1.14 to 1.19) 0.0001 |
| N06A, antidepressants                  | 1.11 (1.09 to 1.13) 0.0001 | 1.14 (1.12 to 1.15) 0.0001 | 1.16 (1.14 to 1.17) 0.0001 | 1.15 (1.13 to 1.16) 0.0001 |
| N06B, psychostimulants                | 0.98 (0.92 to 1.05) 0.56 | 1.05 (0.98 to 1.13) 0.14 | 1.08 (1.00 to 1.15) 0.039 | 1.07 (1.00 to 1.15) 0.057 |
| N06C, psycholeptics and psychoanaleptics | 1.30 (1.20 to 1.42) 0.0001 | 1.31 (1.20 to 1.42) 0.0001 | 1.27 (1.17 to 1.39) 0.0001 | 1.26 (1.16 to 1.38) 0.0001 |

Model 1 is the unadjusted model; Model 2 is Model 1 adjusted for age group, education and marital status; Model 3 is Model 2 adjusted for socioeconomic status and income level; Model 4 is Model 3 adjusted for recent pregnancy (in 2017), abortion (in 2016–2017) and sterilisation (before 2017).

ATC, Anatomical Therapeutic Chemical; HC, hormonal contraception.
| Class of psychotropic medication | Number of prescriptions | HC users | HC non-users | P value* | Level of use† | HC users | HC non-users | P value* |
|----------------------------------|-------------------------|----------|--------------|----------|--------------|----------|--------------|----------|
|                                  | One prescription        |          |              |          |              |          |              |          |
| Any psychotropic medication      |                         | 13 269 (4.5%) | 12 696 (4.3%) | 0.0001   |              |          |              |          |
|                                  | ≥2 prescriptions        | 43 572 (14.8%) | 43 072 (14.6%) | 0.179    |              |          |              |          |
| Antipsychotics                   |                         | 3867 (1.5%) | 4273 (1.3%)  | <0.0001  | Low          | 5445 (1.85%) | 5709 (1.94%) | 0.037    |
|                                  |                         |           |              |          | Intermediate | 4385 (1.49%) | 4734 (1.61%) | 0.0008   |
|                                  | ≥2 prescriptions        | 10 548 (3.6%) | 11 694 (4.0%) | <0.0001  | High         | 4582 (1.56%) | 5519 (1.88%) | <0.0001  |
| Anxiolytics                      |                         | 6748 (2.3%) | 6564 (2.2%)  | 0.222    | Low          | 4852 (1.65%) | 4650 (1.58%) | 0.115    |
|                                  |                         |           |              |          | Intermediate | 4503 (1.53%) | 4506 (1.53%) | 2.924    |
|                                  | ≥2 prescriptions        | 6705 (2.3%) | 7001 (2.4%)  | 0.023    | High         | 4098 (1.39%) | 4409 (1.50%) | 0.0022   |
| Hypnotics/sedatives              |                         | 6786 (2.3%) | 6072 (2.1%)  | <0.0001  | Low          | 6865 (2.33%) | 6134 (2.08%) | <0.0001  |
|                                  |                         |           |              |          | Intermediate | 6362 (2.12%) | 5407 (1.84%) | <0.0001  |
| Antidepressants                  |                         | 8395 (2.9%) | 8460 (2.9%)  | 1.233    | Low          | 14 815 (2.52%) | 14 867 (2.53%) | 2.288    |
|                                  |                         |           |              |          | Intermediate | 14 998 (2.55%) | 14 689 (2.50%) | 0.219    |
|                                  | ≥2 prescriptions        | 36 396 (12.4%) | 35 793 (12.2%) | 0.050    | High         | 14 978 (2.54%) | 14 697 (2.50%) | 0.308    |
| Psychostimulants                 |                         | 236 (0.08%) | 276 (0.09%)  | 0.154    | Low          | 617 (0.21%)  | 702 (0.24%)  | 0.058    |
|                                  |                         |           |              |          | Intermediate | 563 (0.19%)  | 612 (0.21%)  | 0.459    |
|                                  | ≥2 prescriptions        | 1604 (0.6%) | 1669 (0.6%)  | 0.512    | High         | 617 (0.21%)  | 602 (0.21%)  | 2.003    |
| Psycholeptics–psychoanaleptics in combination | One prescription | 809 (0.28%) | 673 (0.23%)  | 0.0008   | Low          | 804 (0.27%)  | 658 (0.22%)  | 0.0003   |
|                                  |                         |           |              |          | Intermediate | 538 (0.18%)  | 553 (0.19%)  | <0.0001  |

*P values are from overall χ² tests, and from post hoc pairwise comparisons adjusted for multiple testing.
†Level of use of psychotropic medications was based on quantiles of purchased DDD (tertiles for antipsychotics, anxiolytics, antidepressants and psychostimulants; 50th percentile for hypnotics/sedatives, and 60th percentile for psycholeptics and psychoanaleptics in combination).

ATC, Anatomical Therapeutic Chemical; DDD, defined daily dose; HC, hormonal contraception.
Table 4  Associations between number of prescriptions of psychotropic medications between 2013 and 2016, and hormonal contraception use in 2017

| Class of psychotropic medication | Number of prescriptions | Model 1 |  | Model 2 |  | Model 3 |  | Model 4 |  |
|---------------------------------|-------------------------|---------|---|---------|---|---------|---|---------|---|
|                                 |                         | OR      | 95% CI | P value | OR      | 95% CI | P value | OR      | 95% CI | P value | OR      | 95% CI | P value |
| Any psychotropic medication     | One prescription        | 1.05    | 1.02 to 1.08 | 0.0001 | 1.06    | 1.04 to 1.09 | <0.0001 | 1.04    | 1.01 to 1.06 | 0.0072 | 1.03    | 1.01 to 1.06 | 0.014 |
|                                 | ≥2 prescriptions        | 1.02    | 1.00 to 1.03 | 0.0295 | 1.04    | 1.03 to 1.06 | <0.0001 | 1.08    | 1.06 to 1.09 | <0.0001 | 1.07    | 1.06 to 1.09 | <0.0001 |
| Antipsychotics                  | One prescription        | 0.90    | 0.86 to 0.94 | <0.0001 | 0.95    | 0.91 to 1.00 | 0.0335 | 0.96    | 0.92 to 1.01 | 0.104  | 0.96    | 0.92 to 1.00 | 0.069 |
|                                 | ≥2 prescriptions        | 0.90    | 0.88 to 0.92 | <0.0001 | 0.97    | 0.94 to 1.00 | 0.0198 | 1.06    | 1.03 to 1.09 | 0.0001 | 1.06    | 1.03 to 1.09 | 0.0002 |
| Anxiolytics                     | One prescription        | 1.03    | 0.99 to 1.06 | 0.121  | 1.04    | 1.00 to 1.08 | 0.0295 | 1.04    | 1.01 to 1.08 | 0.0214 | 1.04    | 1.00 to 1.07 | 0.055 |
|                                 | ≥2 prescriptions        | 0.96    | 0.93 to 0.99 | 0.0117 | 1.02    | 0.98 to 1.05 | 0.309  | 1.10    | 1.06 to 1.14 | <0.0001 | 1.10    | 1.06 to 1.14 | <0.0001 |
| Hypnotics/sedatives             | One prescription        | 1.12    | 1.09 to 1.16 | <0.0001 | 1.12    | 1.08 to 1.16 | <0.0001 | 1.09    | 1.05 to 1.13 | <0.0001 | 1.09    | 1.05 to 1.13 | <0.0001 |
|                                 | ≥2 prescriptions        | 1.16    | 1.12 to 1.20 | <0.0001 | 1.16    | 1.11 to 1.20 | <0.0001 | 1.18    | 1.14 to 1.23 | <0.0001 | 1.19    | 1.15 to 1.24 | <0.0001 |
| Antidepressants                 | One prescription        | 1.00    | 0.96 to 1.03 | 0.724  | 1.02    | 0.99 to 1.06 | 0.165  | 1.01    | 0.98 to 1.04 | 0.479  | 1.01    | 0.98 to 1.04 | 0.575 |
|                                 | ≥2 prescriptions        | 1.02    | 1.00 to 1.04 | 0.0178 | 1.04    | 1.03 to 1.06 | <0.0001 | 1.07    | 1.06 to 1.09 | <0.0001 | 1.07    | 1.06 to 1.09 | <0.0001 |
| Psychostimulants                | One prescription        | 0.86    | 0.72 to 1.02 | 0.077  | 0.92    | 0.77 to 1.09 | 0.323  | 0.95    | 0.79 to 1.13 | 0.535  | 0.94    | 0.79 to 1.13 | 0.510 |
|                                 | ≥2 prescriptions        | 0.96    | 0.90 to 1.03 | 0.252  | 1.03    | 0.96 to 1.10 | 0.405  | 1.05    | 0.98 to 1.12 | 0.213  | 1.04    | 0.97 to 1.12 | 0.247 |
| Psycholeptics and psychoanalactics | One prescription | 1.20    | 1.09 to 1.33 | 0.0004 | 1.19    | 1.07 to 1.32 | 0.0012 | 1.17    | 1.06 to 1.30 | 0.0025 | 1.18    | 1.06 to 1.31 | 0.0024 |
|                                 | ≥2 prescriptions        | 1.30    | 1.16 to 1.45 | <0.0001 | 1.31    | 1.17 to 1.47 | <0.0001 | 1.35    | 1.21 to 1.52 | <0.0001 | 1.37    | 1.22 to 1.53 | <0.0001 |

Model 1 is the unadjusted model; Model 2 is Model 1 adjusted for age group, education and marital status; Model 3 is Model 2 adjusted for socioeconomic status and income level; Model 4 is Model 3 adjusted for recent pregnancy (in 2017), abortion (in 2016–2017) and sterilisation (before 2017).

HC, hormonal contraception.
(20–29 years), but higher in middle-age women (online supplemental figures 4 and 5).

Psychotropic medications and HC types
Supplementary Figure 6 illustrates the types of HC used in 2017 by occasional and regular users of psychotropic medications between 2013 and 2016 (online supplemental figure 6).

In univariable and multivariable (adjusted for age group, marital and socioeconomic status, education and income level, recent pregnancy or induced abortion) multinomial logistic regression models, when fixed combinations of progestogens and oestrogens for systemic use (ATC: G03AA) was the reference category, women either occasionally (figure 1) or regularly (figure 2) using almost any class of psychotropic medications had higher odds of using any other types of HC (such as the LNG-IUS and, to a lesser extent, vaginal ring and progestogens for systemic use). The main exception was a reduced (or a tendency to reduced) relative risk ratio of use of sequential preparations for systemic use (G03AB) in regular users of anxiolytics and hypnotics/sedatives in a fully adjusted model.

The results were substantially confirmed in unadjusted and, to a lesser extent, adjusted models using quantiles of redeemed DDD (online supplemental table 2).

DISCUSSION
According to our results, the current as well as past uses of psychotropic medications are associated with higher odds of using HC among Finnish girls and women of fertile age. This association holds also in relation to regular and, although to a lesser extent, occasional use of psychiatric medications during the four previous years. This study additionally indicates that the use of psychotropic
medications is associated with the type of contraceptive chosen.

Our study has a number of limitations. First, misclassification of HC use cannot be ruled out. Because we had no information on contraception use before 2017, it is possible that a number of women in the control group were in fact using HC, especially long-acting reversible contraception (LARC) methods, which may have been prescribed or inserted before 2017. The lack of information on HC use before 2017 further limits the interpretability of the detected prospective associations, which can in fact reflect a more complex path between (unidentified) HC use between 2013 and 2016, psychiatric problems in the same period and HC use in 2017. It is also possible that the detected associations in fact result from a selection bias, where unobserved confounding may underlie the choice of using HC, especially in young women. Additionally, we lacked information on the use of contraceptives that do not require a prescription, such as copper IUD or condoms, or on young women who obtained free contraception as part of municipal programmes. We may expect that a proportion of women with psychiatric disorders, being usually high users of healthcare services, may have received free-of-charge (and thus without a prescription) contraception, and thus being erroneously classified as non-users. However, if this were the case, it would even further support our results. Likewise, because more than 20% of women who receive free contraception opt for a LARC method such as the LNG-IUS or contraceptive implants, the same bias may concern the analyses on the HC types. Additionally our results cannot be generalised to women with psychiatric disorders. Because our predictor of interest was a prescription of psychotropic medications, women with mild conditions, who do not need a pharmacological treatment, as well as women with psychiatric disorders, being usually high users of healthcare services, may have received free-of-charge (and thus without a prescription) contraception, and thus being erroneously classified as non-users. However, if this were the case, it would even further support our results. Likewise, because more than 20% of women who receive free contraception opt for a LARC method such as the LNG-IUS or contraceptive implants, the same bias may concern the analyses on the HC types.
more severe disorders but not yet receiving (or with poor adherence to) a pharmacological treatment, may have been included in the reference group. However, by distinguishing regular versus occasional past psychiatric prescriptions, and by conducting sensitivity analyses using the amount of purchased drug, we partly took into account these factors. Similarly, it cannot be excluded that users of hormonal contraceptives prefer pharmacological treatment strategies for psychiatric disorders, whereas non-user of hormonal contraceptives with psychiatric diagnoses prefer non-pharmacological treatments such as psychotherapy.

P values in the study are reported with descriptive purpose only, without intent to do formal statistical testing based on them; hence, no adjustments for multiple testing have been performed; however, results have been interpreted using estimates and their CIs.

Moreover, given the observational nature of the data, causality cannot be determined in the associations identified.

Among the strengths of the study, our population was highly representative, including more than half of fertile-aged women in Finland. Additional strengths are the use of register data with proven good validity and reliability, and the combination of a cross-sectional and longitudinal retrospective design, which provides stability to our predictor of interest. Our findings are further supported by the use of different approaches to determine levels of use of psychotropic medications.

To the best of our knowledge, this is the first study to examine, on a nationwide scale, the associations between the concurrent and past class-specific use of psychotropic medications and class-specific HC use. The observation of higher odds for HC use among girls and women using psychotropic medications contrasts with large part of the available evidence on psychiatric disorders. In fact, previous studies reported associations between psychiatric disorders and risky sexual behaviour, lower contraceptive compliance, contraceptive non-use, unintended pregnancy and use of less effective methods.

However, other works showed either no relationships between depressive/anxiety symptoms or psychological distress and inconsistent use of contraception or use of less effective methods, or even higher odds of choosing a more effective method.

On the other hand, our results are substantially in line with those of the few studies that have specifically looked at associations between HC and use of psychotropic medications, although from a different perspective. Two Swedish register-based studies have shown positive associations between some types of combined HCs and progestogen-only HCs, and antidepressant use among women aged 16–31 years, with the highest odds in the youngest age group (16–19 years).

In particular, the authors reported more pronounced associations with antidepressant use among young women using LARC methods (IUS, implants, injections and transdermal patch). However, because the studies did not take into account the sequence of drugs used, no assumption on the directionality of the associations could be made.

Another recent Swedish register-based study confirmed higher subsequent use of antidepressants in HC users, especially in contexts composed by immigrant, low-income women with previous mental issues. The same authors had previously found an OR of 1.34 for subsequent psychotropic drug use in young women (12–30 years) using HC compared with non-users, with the strongest association in adolescents (but no association after adolescence). Again, because all these, including ours, are epidemiological studies based on observational data, assumptions on causality and directionality of the associations cannot be made.

Although not totally comparable, our findings, supported by the use of both a cross-sectional and a longitudinal design, suggest that girls and women with repeated prescriptions of psychotropic medications (and as such at least partly representative of those with a psychiatric disorder) have good access to, and are well aware of contraceptive options in Finland. The use of contraception was especially higher among teenagers who used psychiatric medications than in their peers who were not using the same drugs. However, it tended to invert the figure for the young age group (20–24 years), possibly suggesting that the adequate psychiatric and reproductive counselling and education likely offered through the school system may not be completely continued after high school.

The observation of a relationship between the use of psychotropic drugs and the type of contraceptive chosen provides additional information on the reproductive health status of these women. Specifically, the use of psychiatric medications was associated with higher odds of using types of contraception other than the monophasic OCs, and especially LARC methods such as the LNG-IUS, as well as vaginal ring and progestogens for systemic use including implants. Because the oral preparations in particular require daily motivation, the use of less user-dependent LARC methods may be advisable especially in women who, because of their psychological challenges, may have difficulty with a method necessitating daily remembering. This is in line with the observation of lower odds of using sequential preparations (highly user-dependent) in regular users of anxiolytics and hypnotics/sedatives.

It could be argued that our findings may be affected by a healthcare user bias. In other words, it is likely that women suffering from and seeking help for their psychiatric disorders, and thus receiving a pharmacological treatment, represent a more conscious and healthy subgroup of this population. As such, they may obtain a better control of their symptoms (as compared with their peers not using psychiatric medications), and thus also of other areas of their lives, including contraception. Moreover, because more likely to visit healthcare services, they may also be more likely to receive and adhere to any medical prescription. Reciprocally, women who use HC
are likely to see healthcare providers, and thus to have their psychiatric symptoms diagnosed and pharmacologically treated. This assumption is supported by the observation that the detected associations were substantively consistent for women with either repeated prescriptions or belonging to the highest DDD group, but almost completely non-existent for occasional users or those with the lowest purchased DDD. However, in our sensitivity analyses part of the associations hold also in the group of women with intermediate/low use (eg, in the case of hypnotic/sedatives, antidepressants, psycholeptics and psychoanalectics) possibly including, in addition to occasional users, those with poor compliance to psychopharmacological treatment.

Toffol et al. BMJ Open 2022;12:e053837. doi:10.1136/bmjopen-2021-053837

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, build, adapt and commercial use the work under the CC BY-NC 4.0 licence, as long as the original work is properly cited. The terms of the licence are available at http://creativecommons.org/licenses/by-nc/4.0/

Ethics approval The study was approved by the Ethics Committee of the Faculty of Medicine, University of Helsinki (3/2018). Because this is a register-based study, no individual consent is needed.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data may be obtained from a third party and are not publicly available. The data that support the findings of this study are available from Statistics Finland, the Social Insurance Institution and the Finnish Cancer Registry, but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are, however, available from the authors upon reasonable request and with permission of FinData (https://www.findata.fi/en/).

REFERENCES

1. McCloskey LR, Wisner KL, Cattan MK, et al. Contraception for women with psychiatric disorders. *Am J Psychiatry* 2021;178:247–55.
2. Duke JM, Sibbritt DW, Young AF. Is there an association between the use of oral contraception and depressive symptoms in young Australian women? *Contraception* 2007;75:27–31.
3. Cheslack-Postava K, Keyes KM, Lowe SR, et al. Oral contraceptive use and psychiatric disorders in a nationally representative sample of women. *Arch Womens Ment Health* 2015;18:103–11.
4. Skovlund CW, Merch LS, Kessing LV, et al. Association of hormonal contraceptive use with depression. *JAMA Psychiatry* 2016;73:1154–62.
5. Skovlund CW, Merch LS, Kessing LV, et al. Association of hormonal contraception with suicide attempts and suicides. *Am J Psychiatry* 2018;175:336–42.
6. Edwards AC, Lönn SL, Crump C, et al. Oral contraceptive use and risk of suicidal behavior among young women. *Psychol Med* 2020:1–8.
7. Anderl C, Li G, Chen FS. Oral contraceptive use in adolescence predicts lasting vulnerability to depression in adulthood. *J Child Psychol Psychiatry* 2020;61:148–56.
8. Ramakrishna S, Caspi A, Dickson N, et al. Psychiatric disorders and risky sexual behaviour in young adulthood: cross sectional study in birth cohort. *BMJ* 2000;321:263–6.
9. Zink TM, Shireman TI, Ho M, et al. High-risk teen compliance with prescription contraception: an analysis of Ohio Medicaid claims. *J Pediatr Adolesc Gynecol* 2002;15:15–21.
10. Walsemann KM, Perez AD. Anxiety's relationship to inconsistent use of oral contraceptives. *Health Educ Behav* 2006;33:197–214.
11. Garbers S, Correa N, Tobier N, et al. Association between symptoms of depression and contraceptive method choices among low-income women at urban reproductive health centers. *Matern Child Health J* 2010;14:102–9.
12. Vafai Y, Steinberg JR. The effects of preabortion depressive symptoms on postabortion contraceptive effectiveness level chosen among women seeking abortions. *Contraception* 2018;97:335–40.
13. Hall KS, White Katharine O’Connell, Rickert VI, et al. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. *Contraception* 2012;86:518–25.
14 Stidham Hall K, Moreau C, Trussell J, et al. Young women’s consistency of contraceptive use — does depression or stress matter? *Contraception* 2013;88:641–9.

15 Pope CJ, Ononen K, Mazmanian D, et al. The hormonal sensitivity hypothesis: a review and new findings. *Med Hypotheses* 2017;102:69–77.

16 Bengtsson H, Lundin C, Gemzell Danielsson K, et al. Ongoing or previous mental disorders predispose to adverse mood reporting during combined oral contraceptive use. *Eur J Contracept Reprod Health Care* 2018;23:46–51.

17 Toffol E, But A, Heikinheimo O, et al. Associations between hormonal contraception use, sociodemographic factors and mental health: a nationwide, register-based, matched case-control study. *BMJ Open* 2020;10:e040072.

18 Kanta Services. What are the Kanta services? Available: https://www.kanta.fi/en/what-are-kanta-services [Accessed 24 Mar 2021].

19 Turner H, Firth D. Generalized nonlinear models in R: an overview of the gnm package. R package version 1.1–1, 2020. Available: https://CRAN.R-project.org/package=gnm [Accessed 24 Mar 2021].

20 R Core Team. R: A language and environment for statistical computing [online]. Vienna, Austria: R Foundation for Statistical Computing, 2019. Available: https://www.R-project.org/

21 Gyllenbergh F, Saloartists T, But A, et al. Predictors of choosing long-acting reversible contraceptive methods when provided free-of-charge - A prospective cohort study in Finland. *Contraception* 2020;101:370–5.

22 Tubman JG, Gil AG, Wagner EF, et al. Patterns of sexual risk behaviors and psychiatric disorders in a community sample of young adults. *J Behav Med* 2003;26:473–500.

23 Brown A, Yung A, Cosgrove E, et al. Depressed mood as a risk factor for unprotected sex in young people. *Australas Psychiatry* 2006;14:310–2.

24 DiClemente RJ, Wingood GM, Crosby RA, et al. A prospective study of psychological distress and sexual risk behavior among black adolescent females. *Pediatrics* 2001;108:e85.

25 Lehrer JA, Shrier LA, Gortmaker S, et al. Depressive symptoms as a longitudinal predictor of sexual risk behaviors among US middle and high school students. *Pediatrics* 2006;118:189–200.

26 Hall KS, Moreau C, Trussell J, et al. Role of young women’s depression and stress symptoms in their weekly use and nonuse of contraceptive methods. *J Adolesc Health* 2013;53:241–8.

27 Hall KS, Kusunoki Y, Gatry H, et al. The risk of unintended pregnancy among young women with mental health symptoms. *Soc Sci Med* 2014;100:62–71.

28 Berenson AB, Breitkopf CR, Wu ZH. Reproductive correlates of depressive symptoms among low-income minority women. *Obstet Gynecol* 2003;102:1310–7.

29 Bello JK, Salas J, Meyer D, et al. Mental health diagnoses and early removal of long-acting reversible contraception. *J Affect Disorder* 2020;262:333–6.

30 Steinberg JP, Tschann JM, Henderson JT, et al. Psychological distress and post-abortion contraceptive method effectiveness level chosen at an urban clinic. *Contraception* 2013;88:717–24.

31 Francis J, Pressler L, Malbon K, et al. An exploratory analysis of contraceptive method choice and symptoms of depression in adolescent females initiating prescription contraception. *Contraception* 2015;91:336–43.

32 Faisal-Cury A, Menezes PR, Huang H. The relationship between perinatal psychiatric disorders and contraception use among postpartum women, *Contraception* 2013;88:498–502.

33 Nelson DB, Zhao H, Corrado R, et al. Preventing unintended pregnancy among young sexually active women: recognizing the role of violence, self-esteem, and depressive symptoms on use of contraception. *J Womens Health* 2017;26:352–60.

34 Wirhén A-B, Foldemo A, Josefsson A, et al. Use of hormonal contraceptives in relation to antidepressant therapy: a nationwide population-based study. *Eur J Contracept Reprod Health Care* 2010;15:41–7.

35 Lindberg M, Foldemo A, Josefsson A, et al. Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. *Eur J Contracept Reprod Health Care* 2012;17:106–18.

36 Zettermark S, Khalaf K, Perez-Vicente R, et al. Population heterogeneity in associations between hormonal contraception and antidepressant use in Sweden: a prospective cohort study applying intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy (MAIIDA). *BMJ Open* 2021;11:e049553.

37 Zettermark S, Perez Vicente R, Merlo J. Hormonal contraception increases the risk of psychotropic drug use in adolescent girls but not in adults: a pharmacoepidemiological study on 800 000 Swedish women. *PLoS One* 2018;13:e0194773.